Biomarin

BioMarin: So You’re Saying There’s a Chance?
Barron's
Wed, 11/25/15 - 11:31 am
Biomarin
Duchenne Muscular Dystrophy
drisapersen
Kyndrisa
FDA
BioMarin Duchenne drug appears destined for failure after brutal FDA meeting
BioPharma Dive
Wed, 11/25/15 - 10:53 am
Biomarin
Duchenne Muscular Dystrophy
FDA
advisory panels
drisapersen
​The first drug for Duchenne will be reviewed at the FDA today: Why it matters
Bizjournals.com
Tue, 11/24/15 - 09:51 am
FDA
Biomarin
advisory panels
Duchenne Muscular Dystrophy
Kyndrisa
drisapersen
BioMarin FDA Panel Live Blog
TheStreet.com
Tue, 11/24/15 - 09:06 am
Biomarin
FDA
advisory panels
Duchenne Muscular Dystrophy
drisapersen
Duchenne moms say FDA documents ‘widen the divide’ between drugs by BioMarin, Sarepta
Bizjournals.com
Fri, 11/20/15 - 06:19 pm
Duchenne Muscular Dystrophy
FDA
eterplirsen
drisapersen
Biomarin
Sarepta Therapeutics
FDA staff unveils strongly critical review of BioMarin Duchenne drug ahead of crucial meeting
BioPharma Dive
Fri, 11/20/15 - 11:11 am
FDA
Biomarin
Duchenne Muscular Dystrophy
drisapersen
Experts say Sarepta has a clear edge over BioMarin in Duchenne drug battle
Bizjournals.com
Thu, 11/5/15 - 12:47 pm
Sarepta Therapeutics
Biomarin
Duchenne Muscular Dystrophy
eteplirsen
drisapersen
FDA ‘Weirdness?’ Separate meetings for BioMarin and Sarepta DMD drugs
Pharmalot
Thu, 10/15/15 - 03:59 pm
FDA
Biomarin
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
drisapersen
​Sarepta’s competitor on Duchenne drug could get a two-month head start on sales
Bizjournals.com
Wed, 10/14/15 - 02:23 pm
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Biomarin
eteplirsen
drisapersen
Sarepta Therapeutics vs. BioMarin Pharmaceutical: Which Company Will Win the DMD Race?
Motley Fool
Tue, 10/6/15 - 07:13 pm
Sarepta Therapeutics
Biomarin
Duchenne Muscular Dystrophy
eteplirsen
drisapersen
What It's Like To Have Dinner With BioMarin Executives
Yahoo/Benzinga
Wed, 09/16/15 - 06:12 pm
Biomarin
Sarepta snags priority review status to keep pace with BioMarin in DMD race
Fierce Biotech
Wed, 08/26/15 - 09:28 am
Sarepta Therapeutics
priority review
Duchenne Muscular Dystrophy
FDA
eteplirsen
drisapersen
Biomarin
Why BioMarin hawked a phase III cancer drug to Medivation for $570M
BioPharma Dive
Wed, 08/26/15 - 08:47 am
Biomarin
Medivation
BMN 673
Sarepta, Biomarin vie for DMD approval, priority review voucher
BioPharma Dive
Mon, 08/24/15 - 11:47 am
Sarepta
Biomarin
Duchenne Muscular Dystrophy
FDA
priority review
review vouchers
BioMarin sells its PhIII cancer drug to Medivation for $570M
Fierce Biotech
Mon, 08/24/15 - 11:22 am
Biomarin
Medivation
talazoparib
breast cancer
BRCA1
BRCA2
BioMarin's Big Bet on Muscular Dystrophy Is Already Paying Off
Motley Fool
Sat, 08/22/15 - 09:01 am
Biomarin
Duchenne Muscular Dystrophy
drisapersen
3 Biotech Stocks That Could Be Buyout Targetst
Motley Fool
Fri, 08/21/15 - 09:46 am
Intrexon
Ziopharm
Bluebird Bio
Biomarin
The 5 Most Expensive Drugs in the World in 2015
Motley Fool
Sun, 08/16/15 - 10:32 am
drug pricing
Glybera
Soliris
Naglazyme
Vimizim
Elaprase
Shire
Biomarin
Alexion
uniQure
BioMarin outlines its R&D game plan as Duchenne MD decision nears
Fierce Biotech
Tue, 08/4/15 - 05:51 pm
Biomarin
R&D
Duchenne Muscular Dystrophy
drisapersen
3 Biotech Stocks to Buy With Huge Catalysts Coming Soon
24/7 Wall St
Mon, 08/3/15 - 12:17 pm
Biomarin
drisapersen
Cempra
Solithromycin
antibiotics
Tetraphase Pharmaceuticals
Eravacycline

Pages